MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-14-2026
Ascendis Pharma A/S Gross Profit 2011-2026 | ASND
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Ascendis Pharma A/S
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 625 M | 319 M | 222 M | 39 M | 4.26 M | 6.95 M | 13.4 M | - | - | - | - | 14 M | 20.4 M | 15.6 M | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 625 M | 4.26 M | 128 M |
Quarterly Gross Profit Ascendis Pharma A/S
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 2.58 M | - | - | - | 746 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.58 M | 746 K | 1.66 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Benitec Biopharma
BNTC
|
282 K | $ 10.98 | -4.52 % | $ 452 M |  USA |
 |
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M |  Germany |
 |
Pharming Group N.V.
PHAR
|
113 M | $ 15.36 | -0.71 % | $ 7.59 B |  Niderland |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
5.51 M | - | 2.54 % | $ 160 B |  France |
 |
Tiziana Life Sciences PLC
TLSA
|
3 K | $ 1.21 | -3.97 % | $ 71.5 M |  Britain |
 |
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
4.73 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | USA |
 |
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - |  Russia |
 |
Assembly Biosciences
ASMB
|
79.1 K | $ 28.46 | 3.45 % | $ 319 M | USA |
 |
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
90 K | - | - | $ 7.46 M |  Israel |
 |
BioDelivery Sciences International
BDSI
|
14 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.67 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioMarin Pharmaceutical
BMRN
|
1.34 B | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
ChemoCentryx
CCXI
|
64.9 M | - | - | $ 3.74 B | USA |
 |
Compugen Ltd.
CGEN
|
63.5 M | $ 2.09 | -0.95 % | $ 195 M | Israel |
 |
Coherus BioSciences
CHRS
|
339 M | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
1.07 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
123 M | - | -7.23 % | $ 13 M | USA |
 |
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M | Germany |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
3.94 M | $ 8.6 | -3.8 % | $ 115 M | USA |
 |
Curis
CRIS
|
9.5 M | $ 0.77 | 1.89 % | $ 4.86 M | USA |